_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
The innovation is particularly suited for bone and cartilage repair
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
Paves the way for next-gen ultra-precise gas sensing
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The results were consistent across both the 10 mg and 40 mg treatment arms
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Subscribe To Our Newsletter & Stay Updated
